In the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN) trial, Blank et al. investigated the difference in clinical outcomes between patients receiving ipilimumab (3 mg/kg) in combination with nivolumab (1 mg/kg), a monoclonal antibody against PD-1, in the neoadjuvant vs. adjuvant setting in 20 patients with stage III melanoma with clinically palpable nodal disease. Here, PDCD1 is linked to melanoma.